Dr. James E. Shipley, M.D. brings 20+ years of drug development experience to NovusLife. Dr. Shipley has been a key contributor for more than 30 drug development programs, resulting in five FDA drug approvals. Dr. Shipley's career includes extensive experience in clinical operations, pharmacovigilance, regulatory activities and quality assurance, as well as pharmacology and toxicology.
From January, 2010 until October, 2013, Dr. Shipley served as Chief Medical Officer at Concert Pharmaceuticals, heading clinical programs in diabetic kidney disease and central nervous system disorders. From September, 2004 until December 2009, he served as Senior Vice President of Clinical Development and Medical Affairs at Endo Pharmaceuticals Solutions, Inc. (formerly Indevus Pharmaceuticals Inc.), where he planned and implemented a broad range of clinical programs and regulatory activities for a number of therapeutic areas, resulting in three NDA approvals. Dr. Shipley came to Indevus from Praecis Pharmaceuticals, where he served as Senior Vice President of Clinical Research and lead efforts for programs in oncology and central nervous system disorders. Previously, Dr. Shipley was with Aventis Pharmaceuticals, where his focus was exclusively on development of central nervous system drug candidates. Since 2001, he has served on senior management and corporate executive committees of his respective companies.
Dr. Shipley received his M.D. degree from the University of Pittsburgh, an M.A. in psychology/neuroscience from the University of Western Ontario and an Honors B.A. in psychology from the Pennsylvania State University. Dr. Shipley's post-graduate medical training included a 4-year residency in psychiatry and an NIMH-funded 2-year postdoctoral fellowship in clinical research. Prior to joining the pharmaceutical industry, Dr. Shipley was on the medical faculties of the University of Pittsburgh and the University of Michigan. Dr. Shipley is board certified in psychiatry by the American Board of Psychiatry and Neurology, and additionally by the American Board of Sleep Medicine.